ADB-CHMINACA
Chemical compound
From Wikipedia, the free encyclopedia
ADB-CHMINACA (also known as ADMB-CHMINACA[3] and MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[4][5] It was identified in cannabinoid blends in Japan in early 2015.[6]
- BR: Class F2 (Prohibited psychotropics)[1]
- CA: Schedule II
- DE: Anlage II (Authorized trade only, not prescriptible)
- UK: Class B
- US: Schedule I
- UN: Psychotropic Schedule II[2]
- Illegal in Singapore, Sweden, Switzerland
| |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H30N4O2 |
| Molar mass | 370.497 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Side effects
Legal status
In the United States, ADB-CHMINACA is a Schedule I controlled substance.[15] Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014.[16]
Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.[17]
ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[18]
ADB-CHMINACA is illegal in Switzerland as of December 2015.[19]
Metabolism
Ten ADB-CHMINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Most transformations occurred at the cyclohexylmethyl tail of the compound.[20]